UnitedHealth chief admits US health system ‘does not work as well as it should’ In a New York Times essay, Andrew Witty also says slain healthcare CEO Brian Thompson cared about customers The Guardian - US · Dec 14, 2024
GRAIL: Biotech Stock Targeting $100B Cancer Market GRAIL is a small biotech stock on the rise big time recently. Its innovative technology gives it the opportunity to capitalize on a massive addressable market. MarketBeat · Dec 14, 2024
McKinsey to pay $650m to resolve US investigation into opioid crisis role Consultancy giant agrees to two criminal counts, including for conspiring with drug manufacturers, in DoJ settlement The Guardian - US · Dec 13, 2024
Mckinsey To Pay 0 Million In Purdue Pharma Settlement McKinsey & Company agrees to pay 0 million in settlement for its role in Purdue Pharma's opioid crisis, impacting addiction and overdose prevention efforts. Top News · Dec 13, 2024
McKinsey & Company agrees to pay $650 million to settle federal probe over opioids work McKinsey & Company consulting firm has agreed to pay $650 million to settle a federal investigation into its work for opioids manufacturer Purdue Pharma, according to court papers filed in Virginia The Independent UK · Dec 13, 2024
3 Healthcare Innovators Revolutionizing Patient Care The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading. StockNews.com · Dec 12, 2024
Vifor Pharma to pay £23m to NHS after competition probe into misleading claims The competition watchdog was investigating whether the drugs firm had been spreading misleading information on a rival’s treatment. The Independent UK · Dec 10, 2024
Assessing Biogen: Insights From 19 Financial Analysts Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months. Benzinga · Dec 9, 2024
Worker Reveals Shocking Reason Why Women Should Check The Toilet Paper When in Walmart Washrooms Walmart employee warns women about IV drug users cleaning needles in toilet paper rolls, sparking public health concerns and fear. International Business Times UK · Dec 7, 2024
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair? Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies. MarketBeat · Dec 6, 2024
Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma During the last three months, 5 analysts shared their evaluations of NewAmsterdam Pharma (NASDAQ:NAMS), revealing diverse outlooks from bullish to bearish. Benzinga · Dec 5, 2024
4 Analysts Assess Amylyx Pharma: What You Need To Know During the last three months, 4 analysts shared their evaluations of Amylyx Pharma (NASDAQ:AMLX), revealing diverse outlooks from bullish to bearish. Benzinga · Dec 5, 2024
Warren Buffett's Portfolio Stock Kroger Pauses Buybacks For Albertsons Merger, Narrows FY24 Outlook Kroger pauses share buybacks for the Albertsons merger, misses Q3 sales estimates, and narrows its FY24 EPS guidance. Benzinga · Dec 5, 2024
Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket Shares of Verint Systems Inc. (NASDAQ:VRNT) rose sharply in today's pre-market trading after the company reported a year-over-year increase in third-quarter financial results. Benzinga · Dec 5, 2024
Benzinga · Dec 3, 2024 Danish Medical Marijuana Producer Stenocare To Launch Patented 10mg THC And 10mg CBD Oil In Norway A publicly traded Danish medical marijuana operator Stenocare announced Monday the approval of its innovative product, Astrum 10-10, for sale in Norway. This milestone paves the way for more patients to access the benefits of medical cannabis treatment. Astrum 10-10 is expected to become available to patients within the next…
Benzinga · Dec 3, 2024 Why Is Coherus BioSciences Stock Trading Higher On Tuesday? Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.
MarketBeat · Dec 3, 2024 3 Momentum Stocks Soaring Into 2025 and Beyond Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.
Benzinga · Dec 2, 2024 Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump Pharma companies lobby for changes to Medicare drug price rules, targeting a four-year delay for pills' eligibility. Critics warn it may hinder patient access and innovation.
USA Today Sports Media Group · Dec 2, 2024 Hemi Pharma for Sale: “Hemi Pharma for Sale: Advanced Supplements for Peak Performance” The pursuit of peak performance-whether in athletics, academics, or day-to-day life-has led to an increased demand for supplements that deliver more than just marginal gains. This is where Hemi Pharma for Sale steps in, offering a game-changing ...
Benzinga · Dec 2, 2024 5 Analysts Assess PROCEPT BioRobotics: What You Need To Know In the last three months, 5 analysts have published ratings on PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse range of perspectives from bullish to bearish.
Benzinga · Dec 2, 2024 PTC Therapeutics Signs Exclusive Global License And Collaboration Agreement With Novartis; PTC To Receive Upfront Payment Of $1B, Up To $1.9B In Development, Regulatory And Sales Milestones PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its
StockNews.com · Nov 29, 2024 Eli Lilly (LLY) vs. Catalent (CTLT): Which Pharma Stock Offers Better Returns? The pharma industry is evolving rapidly due to the ever-rising healthcare needs and increasing demand for customized medicine and treatments worldwide. So, let’s analyze Eli Lilly (LLY) and Catalent (CTLT), to determine which pharma stock offers better returns. Read more.
StockNews.com · Nov 29, 2024 3 Biotech Stocks with Promising Pipelines to Watch As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…
StockNews.com · Nov 27, 2024 3 Biotech ETFs for Diversified Innovation Exposure Biotech ETFs provide the perfect balance of high-growth potential and diversified risk, offering investors access to healthcare breakthroughs. Given this backdrop, you might consider three biotech ETFs: iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and First Trust NYSE Arca Biotechnology Index Fund (FBT). Keep reading….
MarketBeat · Nov 27, 2024 2 Generic Drug Stocks Ready to Surge in 2025 Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.